In one paragraphArticle in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 2 institutions in 1 country.
Sarah Mann DanielsonDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-1512-882X Adam R LeffertsDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-2394-7833 Eric NormanDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Emilie H RegnerDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Hanna M SchulzDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Danielle Sansone-PoeDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-7466-9255 Kristine A KuhnDivision of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-6900-4195 University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US
Funding
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS · 1995 to 2026
$32.6MTRAINING PROGRAM IN IMMUNOLOGYT32AI007405 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Laurel L Lenz, Raul Martin Torres · 1991 to 2026
$10.5MResearch Training in Rheumatology INCLUDE Down Syndrome SupplementT32AR007534 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Kristine A. Kuhn · 1986 to 2026
$6.1MCore 2 - Mucosal Immunobiology Core (MIC)P30AR079369 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Vernon Michael Holers · 2021 to 2026
$4.7MDevelopment of colonic intraepithelial lymphocytes and their role in epithelial and immune functionK08DK107905 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI KUHN, KRISTINE A. · 2016 to 2020
$716kLATINO RESEARCH TRAINING FOR HIV/AIDST32AI007534 · NIAID · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI SERRANO-GARCIA, IRMA · 1998 to 2002
$267kThe recruitment and retention of colon intraepithelial lymphocytesF31DK138543 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DANIELSON, SARAH MANN · 2024 to 2025
$76kHHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) AR079369HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK107905HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) AI007405HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) AR007534NIAID NIH HHS T32 AI007405NIAMS NIH HHS P30 AR079369NIAMS NIH HHS T32 AR007534NIDDK NIH HHS F31 DK138543NIDDK NIH HHS K08 DK107905
6 · The paper itselfAbstract
Intraepithelial lymphocytes (IELs) are T cells important for the maintenance of barrier integrity in the intestine. Colon IELs are significantly reduced in both MyD88-deficient mice and those lacking an intact microbiota, suggesting that MyD88-mediated detection of bacterial products is important for the recruitment and/or retention of these cells. Here, using conditionally deficient MyD88 mice, we show that myeloid cells are the key mediators of TCRαβ+ IEL recruitment to the colon. Upon exposure to luminal bacteria, myeloid cells produce sphingosine-1-phosphate (S1P) in a MyD88-dependent fashion. TCRαβ+ IEL recruitment may be blocked using the S1P receptor antagonist FTY720, confirming the importance of S1P in the recruitment of TCRαβ+ IELs to the colon epithelium. Finally, using the TNFΔARE/+ model of Crohn's-like bowel inflammation, we show that disruption of colon IEL recruitment through myeloid-specific MyD88 deficiency results in reduced pathology. Our results illustrate one mechanism for recruitment of a subset of IELs to the colon.
Indexed as
ColonIntestinal MucosaIntraepithelial LymphocytesLysophospholipidsMice, KnockoutMyeloid CellsMyeloid Differentiation Factor 88Receptors, Antigen, T-Cell, alpha-betaSphingosineAnimalsCrohn DiseaseFingolimod HydrochlorideMiceMice, Inbred C57BLFingolimod HydrochlorideLysophospholipidsMyd88 protein, mouseMyeloid Differentiation Factor 88Receptors, Antigen, T-Cell, alpha-betaSphingosinesphingosine 1-phosphate
Identifiers
PMID38568091
PMCPMC11105980
OpenAlexW4393854818
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390